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Hepatocellular carcinoma (HCC) is a major health problem worldwide, and it has a poor prognosis. Extrahepatic metastasis from 
HCC is not unusual, with direct invasion representing the main spreading mode. Sites that are frequently involved are the lung, 
bone, and lymph nodes. There are few reports of HCC invading the distant gastrointestinal tract, especially hematogenously. 
Herein we report a case of sigmoid colon metastasis from HCC. The patient was diagnosed with HCC and treated with 
transcatheter arterial chemoembolization (TACE). Eighteen months after TACE the patient presented with abdominal pain on the 
left lower quadrant, and a CT scan showed an enhanced mass on the sigmoid colon. Immunohistochemical staining revealed that 
a tumor cell was positive for polyclonal carcinoembryonic antigen and weakly positive for hepatocyte antigen, supporting the 
diagnosis of HCC metastasis. The patient underwent anterior resection for the metastatic HCC. (Korean J Hepatol 2010; 
16:397-400)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is a serious health problem 
and has a poor prognosis. HCC accounts for 5.6% of all human 
cancers with more than 1 million deaths annually and the 
incidence of HCC is increasing.
1,2 Despite the implementation of 
surveillance programs for early HCC, most tumors are diagnosed 
at intermediate or advanced stages, and only 30% of patients 
benefit from curative therapies such as resection, liver trans-
plantation, or percutaneous ablation.
2,3
In the previous autopsy series, extrahepatic metastasis was 
present in 30~70% of cases and the major organs involved were 
lung, lymph nodes, bone, and the adrenal gland.
4,5 Interestingly, 
involvement of the gastrointestinal (GI) tract from HCC seldom 
occurs, being found in only 4~6% of cases in the same series
4,5 
and 0.5~2% of cases in another series.
6,7 Among the GI meta-
stasis from HCC, colon metastasis, especially the left-sided 
colon, is very rare and mostly occurs through direct invasion.
8,9
Here, we report on a HCC patient who was treated with trans-
arterial chemoembolization (TACE) and had a solitary metastatic 
tumor from HCC on his sigmoid colon one and a half years after 
initial treatment.
CASE REPORT
A 47-year-old man was admitted with a hepatic mass 
incidentally detected by ultrasound. A computed tomography 
(CT) scan revealed a 1.7 cm-sized mass in the hepatic segment 
VI with enhancement on the arterial phase and early washout on 
the portal phase (Fig. 1A), and a tiny enhancing nodule on the 
arterial phase without early washout on the portal phase in segment 
IV (Fig. 1B). The patient was a hepatitis B virus (HBV) carrier. 
Upon physical examination, superficial lymphadenectasis, 
icteric sclera, liver palm, or spider telangiectasias were not 
observed. The laboratory findings showed a slight elevation of 
transaminase (aspartate aminotransferase: AST 78 IU/L, alanine 398  The Korean Journal of Hepatology Vol. 16. No. 4, December 2010
Figure 1. CT scans performed at the initial diagnosis of HCC. (A) The hepatic mass was a 1.7 cm-sized mass with arterial enhancement 
(arrow) mass in hepatic segment VI, with a patent portal vein and no metastatic lesion evident on CT scans. (B) A tiny subcapsular 
arterial enhancement (arrow) without early washout was noted in segment IV.
Figure 2. Endoscopy image and CT scan of metastatic HCC. (A) Endoscopy revealed a bulging contoured mass at 20 cm from the 
anal verge without a mucosal defect or diverticulum. (B) The CT scan revealed a 4×3.5 cm eccentric mass (arrow) abutting the sigmoid 
colon without lymph node enlargement.
aminotransferase: ALT 50 IU/L) and a mild decrease in platelet 
count (113,000/mm
3). All other values including white blood 
cell, hemoglobin, protein, albumin, bilirubin, and prothrombin 
time were within normal limits. HBV surface antigen (HBsAg) 
and HBV e antigen (HBeAg) were positive but anti-hepatitis C 
virus antibody was negative. The alpha-fetoprotein (AFP) level 
was 365 ng/mL. A percutaneous needle biopsy was performed on 
the mass in segment VI and the pathologic diagnosis of HCC, 
Edmonson-Steiner grade 3, was made. The patient underwent 
transcatheter arterial angiography and chemoembolization (TACE) 
to treat the HCC and differentiate the tiny enhancing nodule from 
another HCC. On angiography, the enhancing nodule was identi-
fied as an AP shunt. After TACE, there had been no evidence of 
tumor recurrence on follow-up CT scans and AFP levels for one 
and a half years. In one and a half years, the patient presented 
with abdominal pain around the left lower quadrant. Physical 
examination was unremarkable and all laboratory findings 
including an AFP level were within normal limits except a mild 
elevation of liver enzymes: AST 46 IU/L and ALT 68 IU/L. On 
colonoscopy, a bulging contoured hard mass was noted in the 
sigmoid colon but the overlying mucosa was intact (Fig. 2A). 
The CT scan revealed a 4×3.5 cm sized, eccentric mass abutting the 
sigmoid colon without any lymph node enlargement (Fig. 2B). 
However, the scan did not show any evidence of recurrence in 
the liver and the portal tract. The patient underwent anterior 
resection and a well-defined subserosal mass, measuring 
5.2×4×3.7 cm, was identified. The cut surface of the mass was 
grayish white, solid, and granular with hemorrhage and necrosis 
(Fig. 3A). The mass extended to the proper muscle layer, how-
ever, the overlying mucosa was intact. Histologic examination 
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Figure 3. Histopathology of metastatic HCC. (A) Gross specimens
of sigmoid colon metastasis showing a well-defined subserosal 
mass. (B) The tumor cells had eosinophilic granular cytoplasms 
and large nuclei containing prominent nucleoli, resembling HCC 
(hematoxylin-eosin stain; ×400), and (C) they were positive 
for polyclonal carcinoembryonic antigen (pCEA) (×100).
demonstrated sheets of large polygonal tumor cells arranged 
in a trabecular pattern. The tumor cells exhibited eosino-
philic, granular cytoplasm and large nuclei containing prominent 
nucleoli, resembling HCC (Fig. 3B). The tumor cells were pos-
itive for polyclonal carcinoembryonic antigen (pCEA, 1:800, Dako, 
Glostrup, Denmark) and weakly positive for hepatocyte antigen 
(1:200, Dako, Denmark), supporting the diagnosis of HCC (Fig. 
3C). There was no regional lymph node metastasis at the time 
of surgery and the patient is free of recurrent disease to date for 
over 4 months.
DISCUSSION
HCC with hematogeous metastasis to colon is very rare. This 
case shows the typical findings of HCC metastasis to sigmoid 
colon.
Extrahepatic metastasis of HCC is increasing with prolonged 
survival and the most frequent sites of metastases are lung, bone, 
and lymph nodes. On the other hand, GI involvement of HCC is 
known to be not common. The major mode of metastasis to the 
GI tract is direct invasion to the contiguous GI tract via adhesion 
to the serosal side by a bulky tumor mass and the most frequently 
involved site was the duodenum, followed by the stomach, colon, 
and jejunum.
6 Rarely, it is hypothesized that HCC may dissem-
inate hematogenously to distant GI tracts. Portal vein thrombosis 
may be the key point of hematogenous spread to other sites.
7,10 In 
our case, it is notable that the HCC was initially a small sized sin-
gle mass without portal vein thrombosis and metastasized to the 
left-sided colon one and a half years after TACE. Hematogenous 
spread was suggested because the metastatic site was distant and 
the lymph nodes were not involved.
Endoscopic findings of GI metastasis from HCC were varied, 
such as a raised and centrally ulcerated lesion, mimicking gastric 
carcinoma, polypoid tumor, or submucosal tumor.
7,11 Therefore, 
immunohistochemical findings are important to differentiate 
HCC from adenocarcinoma in the diagnosis of GI metastasis. 
Typically, in HCC, Cam 5.2 staining is positive whereas AE1/AE3 
staining is negative.
12 Polyclonal CEA is highly specific for the 
lining of the biliary canaliculi.
13 Similarly, AFP is another 
reliable indicator for HCC and it has been reported to be positive 
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in 70~90% of cases.
14 In this case, the colonoscopy showed a 
bulging contoured tumor without any mucosal lesions, suspi-
cious of extrinsic compression. The histopathologic findings were 
consistent with metastatic HCC, showing eosinophilic granular 
cytoplasm and large nuclei containing prominent nucleoli with 
immunopositivity for polyclonal CEA and hepatocyte antigen.
According to previous reports, the interval between the diag-
nosis of HCC and detection of GI tract involvement ranged from 
3 months to 8 years.
6,7,9 Mostly, GI metastasis is found in patients 
with advanced staged HCC. The prognosis of GI involvement 
from HCC is known to be poor with a median survival period of 
7 months.
15 However, it was suggested that treatment of extra-
hepatic metastases may improve survival in some selected HCC 
patients who have good reserved function, intrahepatic tumor 
stage (T0-T2), and negative portal vein invasion.
16 Similarly, a 
previous study reported that adrenalectomy for metastatic HCC 
resulted in improved survival rate especially in patients with 
well-controlled intrahepatic lesions at the time of adrenal meta-
stasis and good general condition.
17 Although there is little data 
regarding the efficacy of surgical treatment in patients with hae-
matogenous colon metastasis from HCC, our case was treated 
with surgical management for the metastatic HCC because the 
patient had good hepatic reserved function and no other meta-
static lesions. The patient has been free of recurrent disease to 
date for over 4 months.
In conclusion, HCC with GI metastasis is uncommon and rarely 
spreads hematogenously to distant GI tracts. To date, the 
previously reported colonic metastases were located to the right 
side of the colon. Herein, to the best of our knowledge, we report 
the first case of solitary left-sided sigmoid colonic metastasis 
from HCC treated with surgical resection.
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